Signal active
Bio
Brigitte Smith is the Co-Founder and Managing Partner at GBS since 1996. Brigitte has twenty years’ experience in venture capital, business strategy and start-up company operations. Brigitte has been investing and managing investments for GBS’s $450m of life science specialised venture capital funds since 1998.
Brigitte is on the board of GBS portfolio companies AirXpanders Inc, Endoluminal Sciences Pty Ltd, Neuromonics Pty Ltd, Proacta Inc, and Vivive Inc.
Brigitte was the founding Investor and Chair of Pharmaxis Pty Ltd.
Prior to founding GBS Brigitte worked in the US and Australia in operating roles with early stage technology based companies and at Bain & Company as a Strategic Management Consultant.
Brigitte has a B.Chem Eng (Honours) from the University of Melbourne and as a Fulbright Scholar completed a MBA (Honours) from the Harvard Business School and a MALD from the Fletcher School of Law and Diplomacy, both in Boston, USA.
Location
Melbourne, Victoria, Australia, Oceania
Social
Primary Organization
1996
63
18
13
1-10
Venture Capital
Jobs history
0
N/A
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Brigitte Smith is the Co-Founder & Managing Partner at GBS Ventures, based in Australia, Oceania. With a background in Venture Capital, Brigitte Smith has a rich history of leadership and innovation. Brigitte Smith studied Bachelor's Degree Chemical Engineering @ University of Melbourne. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
12
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
May 07, 2015 | Moximed | Series B - Moximed | GBS Ventures | 33.0M |
Jan 27, 2016 | Moximed | Series B - Moximed | GBS Ventures | 12.6M |
Mar 17, 2017 | Moximed | Series C - Moximed | GBS Ventures | 50.0M |
Aug 16, 2022 | Moximed | Series C - Moximed | GBS Ventures | 40.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.